Abstract
Background
Pembrolizumab is effective in a limited number of patients with advanced urothelial carcinoma (UC). Therefore, we evaluated the prognostic value of clinical biomarkers following pembrolizumab treatment in patients with advanced UC.
Methods
We retrospectively reviewed the medical records of 121 patients with platinum-refractory advanced UC who received pembrolizumab. Inflammation-based prognostic scores before and 6 weeks after the treatment were recorded. The categorical variables influencing overall survival (OS) and objective response rate (ORR) were analyzed.
Results
Multivariate analyses showed that pretreatment Eastern Cooperative Oncology Group (ECOG) performance score (PS), presence of only lymph node metastasis (only LN mets), C-reactive protein (CRP), and neutrophil/lymphocyte ratio (NLR) were independent prognostic factors for OS (P = 0.0077; RR = 2.42, P = 0.0049; RR = 0.36, P = 0.0047; RR = 2.53, and P = 0.0079; RR = 2.33, respectively). The pretreatment risk stratification using ECOG PS, only LN mets, CRP, and NLR was used for estimating the OS (P < 0.0001) and ORR (P < 0.0001). Furthermore, changes in NLR in response to pembrolizumab were significantly associated with the OS (P = 0.0002) and ORR (P = 0.0023). This change was also significantly correlated with OS even in the high-risk group stratified by this pretreatment risk stratification (P = 0.0069).
Conclusions
This pretreatment risk stratification may be used for estimating the OS and ORR of patients with advanced UC treated with pembrolizumab. If changes in NLR in response to pembrolizumab treatment improve, pembrolizumab should be continued.
Similar content being viewed by others
References
Bellmunt J, de Wit R, Vaughn DJ et al (2017) Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 376:1015–1026. https://doi.org/10.1056/NEJMoa1613683
Nishiyama H, Yamamoto Y, Sassa N et al (2020) Pembrolizumab versus chemotherapy in recurrent, advanced urothelial cancer in Japanese patients: a subgroup analysis of the phase 3 KEYNOTE-045 trial. Int J Clin Oncol 25:165–174. https://doi.org/10.1007/s10147-019-01545-4
Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of > 2 years of follow-up. Ann Oncol 30:970–976. https://doi.org/10.1093/annonc/mdz127
Yamamoto Y, Matsuyama H, Matsumoto H et al (2020) Prognostic value of risk stratification using blood parameters for nivolumab in Japanese patients with metastatic renal-cell carcinoma. Jpn J Clin Oncol 50:214–220. https://doi.org/10.1093/jjco/hyz168
Buder-Bakhaya K, Hassel JC (2018) Biomarkers for clinical benefit of immune checkpoint inhibitor treatment-a review from the melanoma perspective and beyond. Front Immunol 9:1474. https://doi.org/10.3389/fimmu.2018.01474
Kitano S, Nakayama T, Yamashita M (2018) Biomarkers for Immune Checkpoint Inhibitors in Melanoma. Front Oncol 8:270. https://doi.org/10.3389/fonc.2018.00270
Sacdalan DB, Lucero JA, Sacdalan DL (2018) Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis. Onco Targets Ther 11:955–965. https://doi.org/10.2147/ott.s153290
Fujii T, Naing A, Rolfo C et al (2018) Biomarkers of response to immune checkpoint blockade in cancer treatment. Crit Rev Oncol Hematol 130:108–120. https://doi.org/10.1016/j.critrevonc.2018.07.010
Cortellini A, Bersanelli M, Buti S et al (2019) A multicenter study of body mass index in cancer patients treated with anti-PD-1/PD-L1 immune checkpoint inhibitors: when overweight becomes favorable. J Immunother Cancer 7(1):57. https://doi.org/10.1186/s40425-019-0527-y
Teraoka S, Fujimoto D, Morimoto T et al (2017) Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with nivolumab: a prospective cohort study. J Thorac Oncol 12(12):1798–1805. https://doi.org/10.1016/j.jtho.2017.08.022
Sato K, Akamatsu H, Murakami E et al (2018) Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. Lung Cancer 115:71–74. https://doi.org/10.1016/j.lungcan.2017.11.019
Kawai T, Sato Y, Makino K et al (2019) Immune-related adverse events predict the therapeutic efficacy of pembrolizumab in urothelial cancer patients. Eur J Cancer 116:114–115. https://doi.org/10.1016/j.ejca.2019.05.017
Yasuoka S, Yuasa T, Nishimura N et al (2019) Initial experience of pembrolizumab therapy in japanese patients with metastatic urothelial cancer. Anticancer Res 39(7):3887–3892. https://doi.org/10.21873/anticanres.13539
Ogihara K, Kikuchi E, Shigeta K et al (2020) The pretreatment neutrophil-to-lymphocyte ratio is a novel biomarker for predicting clinical responses to pembrolizumab in platinum-resistant metastatic urothelial carcinoma patients. Urol Oncol 38(6):602.e601–602.e610. https://doi.org/10.1016/j.urolonc.2020.02.005
Shaul ME, Fridlender ZG (2019) Tumour-associated neutrophils in patients with cancer. Nat Rev Clin Oncol 16:601–620. https://doi.org/10.1038/s41571-019-0222-4
Templeton AJ, Knox JJ, Lin X et al (2016) Change in neutrophil-to-lymphocyte ratio in response to targeted therapy for metastatic renal cell carcinoma as a prognosticator and biomarker of efficacy. Eur Urol 70(2):358–364. https://doi.org/10.1016/j.eururo.2016.02.033
Lalani AA, Xie W, Martini DJ et al (2018) Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma. J Immunother Cancer 6(1):5. https://doi.org/10.1186/s40425-018-0315-0
Qi F, Xu Y, Zheng Y et al (2019) Pre-treatment Glasgow prognostic score and modified Glasgow prognostic score may be potential prognostic biomarkers in urological cancers: a systematic review and meta-analysis. Ann Transl Med 7(20):531. https://doi.org/10.21037/atm.2019.09.160
De Giorgi U, Procopio G, Giannarelli D et al (2019) Association of systemic inflammation index and body mass index with survival in patients with renal cell cancer treated with nivolumab. Clin Cancer Res 25(13):3839–3846. https://doi.org/10.1158/1078-0432.ccr-18-3661
Rogado J, Sanchez-Torres JM, Romero-Laorden N et al (2019) Immune-related adverse events predict the therapeutic efficacy of anti-PD-1 antibodies in cancer patients. Eur J Cancer 109:21–27. https://doi.org/10.1016/j.ejca.2018.10.014
Lavoie JM, Black PC, Eigl BJ (2019) Predictive biomarkers for checkpoint blockade in urothelial cancer: a systematic review. J Urol 202(1):49–56. https://doi.org/10.1097/ju.0000000000000136
Choi Y, Kim JW, Nam KH et al (2017) Systemic inflammation is associated with the density of immune cells in the tumor microenvironment of gastric cancer. Gastric Cancer 20(4):602–611. https://doi.org/10.1007/s10120-016-0642-0
Morizawa Y, Miyake M, Shimada K et al (2018) Correlation of immune cells and cytokines in the tumor microenvironment with elevated neutrophil-to-lymphocyte ratio in blood: an analysis of muscle-invasive bladder cancer. Cancer Invest 36(7):395–405. https://doi.org/10.1080/07357907.2018.1506800
Zou JM, Qin J, Li YC et al (2017) IL-35 induces N2 phenotype of neutrophils to promote tumor growth. Oncotarget 8(20):33501–33514. https://doi.org/10.18632/oncotarget.16819
Fridlender ZG, Albelda SM (2012) Tumor-associated neutrophils: friend or foe? Carcinogenesis 33(5):949–955. https://doi.org/10.1093/carcin/bgs123
Acknowledgements
We thank the staff who collected the clinical data from the Kumamoto University hospital and affiliated hospitals of Yamaguchi University Hospital.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
Matsuyama H has an offer of Honorarium, Research Grant from MSD. No potential conflicts of interest were disclosed by the other authors.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
The original publication has been revised for including missing Electronic Supplementary Material.
Supplementary Information
Below is the link to the electronic supplementary material.
About this article
Cite this article
Yamamoto, Y., Yatsuda, J., Shimokawa, M. et al. Prognostic value of pre-treatment risk stratification and post-treatment neutrophil/lymphocyte ratio change for pembrolizumab in patients with advanced urothelial carcinoma. Int J Clin Oncol 26, 169–177 (2021). https://doi.org/10.1007/s10147-020-01784-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-020-01784-w